Ketoacids during hemodialysis
Completed
- Conditions
- End-stage renal disease
- Registration Number
- NL-OMON26423
- Lead Sponsor
- Maastricht University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Aged >18 years
-Ability to provide written informed consent
-Hemodialysis treatment for >3 months
-Well-functioning arteriovenous shunt in upper or lower arm
Exclusion Criteria
-Hospitalization <1 months prior to study period
-Missed hemodialysis procedure <1 month prior to study period
-Active inflammatory disease / malignancies
-Uncontrolled hypertension (>200/100mm Hg) or arrhythmia
-Previous episodes of intradialytic hypotension related to food intake
-Allergies to milk proteins
-Dysphagia
-Pregnancy
-Cognitive disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint in this study will be the net AA balance over the forearm, calculated by subtracting the venous from arterial AA concentrations.
- Secondary Outcome Measures
Name Time Method Secondary study parameters include plasma and breath L-(ring-13C6)-phenylalanine enrichments and AA concentrations in spent dialysate.